格隆汇11月18日丨根据联交所最新权益披露资料显示，2025年11月11日，中远海控(01919.HK)获BlackRock, Inc.在场内以每股均价14.1925港元增持好仓 215.35万股，涉资约3056.35万港元。 | 表格序號 | 大股東/董事/最高行政人員名 作出披露的買入 / 賣出或涉及的 每股的平均價 | | | | 持有權益的股份數目 佔已發行的有關事件的日 相關法國 | | | | --- | --- | --- | --- | --- | --- | --- | --- | | | | 只发 | 股份數目 | | （請参閱上犹*註 有投票權股期(日/月/ | | 份權益 | | | | | | | 出 份百分比 | | | | CS20251114E00364 | BlackRock, Inc. 2.153,500(L | 1101(L) | | HKD 14.1925 | 173.507.843(L) | 6.02(L)11/11/2025 | | | | | | | | 14,329,000(S) | 0.50(S) | | | 股份代號: | 01919 | | --- | - ...

Core Viewpoint - Heptagon Pharmaceuticals (2142.HK) saw a 9% increase in stock price, reaching a historical high of HKD 16.06, following a mid-term report showing over 50 times year-on-year profit growth [1] Group 1: Financial Performance - The company reported a mid-term profit growth exceeding 50 times year-on-year, indicating strong financial performance [1] Group 2: Strategic Investments - Singapore's Government Investment Corporation (GIC) participated in a placement as a strategic investor on August 29, investing approximately HKD 511 million to acquire 45.022 million shares [1] - This marks the second major global institution to heavily invest in Heptagon Pharmaceuticals this year, following AstraZeneca's strategic investment in March, where it subscribed to 9.15% of newly issued shares at approximately HKD 10.74 per share, a 37.2% premium over the closing price on the day of the agreement [1]